Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wyeth Prevnar Vaccine: First Target Group Is 7 Mil. Infants Under Two

Executive Summary

Wyeth-Lederle's Prevnar launch in early March will initially be aimed at the approximately 7 mil. children in the U.S. under two years of age and several high-risk and minority populations.

You may also be interested in...



FDA Still Not Comfortable With New Vaccine Adjuvants, Industry Veterans Say

The wave of new adjuvant-boosted vaccines under development promises to protect new and broader populations against a host of previously elusive pathogens - including pandemic flu. However, until FDA has more experience with these novel combinations, the regulatory hurdles will remain high, speakers warned at the recent Immunotherapeutics & Vaccine Summit in Cambridge, Mass

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Latest News
See All
UsernamePublicRestriction

Register

PS035647

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel